株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腎性貧血治療の世界市場

Global Market Study on Renal Anemia Treatment: Development of Novel HIF Stabilizers & Approval of Cost-effective Biosimilar Drugs Expected to Push Growth

発行 Persistence Market Research 商品コード 803227
出版日 ページ情報 英文 201 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
腎性貧血治療の世界市場 Global Market Study on Renal Anemia Treatment: Development of Novel HIF Stabilizers & Approval of Cost-effective Biosimilar Drugs Expected to Push Growth
出版日: 2019年01月24日 ページ情報: 英文 201 Pages
概要

当レポートでは、世界の腎性貧血治療市場について調査分析し、市場概要、セグメント別の市場分析と予測、地域別の市場分析と予測、競合情勢など、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場について

  • 市場の定義
  • 市場分類

第3章 腎性貧血治療市場の機会分析

  • マクロ経済的要因
  • 機会分析

第4章 市場の背景

  • 市場力学
    • 成長要因
    • 阻害要因
    • 動向

第5章 主な内容

  • 主な規制
  • パイプライン分析

第6章 世界経済の見通し

  • 国内総生産:地域および国別

第7章 北米市場の分析と予測

  • イントロダクション
  • 過去の市場と分析:国別
    • 米国
    • カナダ
  • 市場と予測:国別
  • 過去の市場:製品タイプ別
    • 鉄分補充保健薬
    • 赤血球生成促進剤(ESA製剤)
  • 市場予測:製品タイプ別
  • 過去の市場:投与ルート別
    • 経口
    • 非経口
  • 市場予測:投与ルート別
  • 過去の市場と動向分析:流通チャネル別
    • 病院薬局
    • 小売薬局
    • 通販薬局
  • 市場と予測:流通チャネル別
  • 市場の魅力分析
    • 国別
    • 製品タイプ別
    • 投与ルート別
    • 流通チャネル別
  • 推進要因と制約:影響分析

第8章 ラテンアメリカ市場の分析と予測

  • イントロダクション
  • 過去の市場動向と分析:国別
    • アルゼンチン
    • ブラジル
    • メキシコ
    • ラテンアメリカの他の地域
  • 市場と予測:国別
  • 過去の市場:製品タイプ別
    • 鉄分補充保健薬
    • 赤血球生成促進剤(ESA製剤)
  • 市場予測:製品タイプ別
  • 過去の市場:投与ルート別
    • 経口
    • 非経口
  • 市場予測:投与ルート別
  • 過去の市場と動向分析:流通チャネル別
    • 病院薬局
    • 小売薬局
    • 通販薬局
  • 市場と予測:流通チャネル別
  • 市場の魅力分析
    • 国別
    • 製品タイプ別
    • 投与ルート別
    • 流通チャネル別
  • 推進要因と制約:影響分析

第9章 欧州市場の分析と予測

  • イントロダクション
  • 地域の動向
  • 過去の市場と動向分析:国別
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • ポーランド
    • 欧州の他の地域
  • 市場と予測:国別
  • 過去の市場:製品タイプ別
    • 鉄分補充保健薬
    • 赤血球生成促進剤(ESA製剤)
  • 市場予測:製品タイプ別
  • 過去の市場:投与ルート別
    • 経口
    • 非経口
  • 市場予測:投与ルート別
  • 過去の市場と動向分析:流通チャネル別
    • 病院薬局
    • 小売薬局
    • 通販薬局
  • 市場と予測:流通チャネル別
  • 市場の魅力分析
    • 国別
    • 製品タイプ別
    • 投与ルート別
    • 流通チャネル別
  • 推進要因と制約:影響分析

第10章 アジア太平洋地域の分析と予測(中国を除く)

  • イントロダクション
  • 過去の市場動向分析:国別
    • インド
    • 日本
    • オーストラリアとニュージーランド
    • その他
  • 市場と予測:国別
  • 過去の市場:製品タイプ別
    • 鉄分補充保健薬
    • 赤血球生成促進剤(ESA製剤)
  • 市場予測:製品タイプ別
  • 過去の市場:投与ルート別
    • 経口
    • 非経口
  • 市場予測:投与ルート別
  • 過去の市場と動向分析:流通チャネル別
    • 病院薬局
    • 小売薬局
    • 通販薬局
  • 市場と予測:流通チャネル別
  • 市場の魅力分析
    • 国別
    • 製品タイプ別
    • 投与ルート別
    • 流通チャネル別
  • 推進要因と制約:影響分析

第11章 中国市場の分析と予測

  • イントロダクション
  • 過去の市場:製品タイプ別
    • 鉄分補充保健薬
    • 赤血球生成促進剤(ESA製剤)
  • 市場予測:製品タイプ別
  • 過去の市場:投与ルート別
    • 経口
    • 非経口
  • 市場予測:投与ルート別
  • 過去の市場と動向分析:流通チャネル別
    • 病院薬局
    • 小売薬局
    • 通販薬局
  • 市場と予測:流通チャネル別
  • 市場魅力分析
    • 製品タイプ別
    • 投与ルート別
    • 流通チャネル別
  • 推進要因と制約:影響分析

第12章 中東・アフリカ市場の分析と予測

  • イントロダクション
  • 過去の市場と動向分析:国別
    • GCC諸国
    • 南アフリカ
    • その他
  • 市場と予測:国別
  • 過去の市場:製品タイプ別
    • 鉄分補充保健薬
    • 赤血球生成促進剤(ESA製剤)
  • 市場予測:製品タイプ別
  • 過去の市場:投与ルート別
    • 経口
    • 非経口
  • 市場予測:投与ルート別
  • 過去の市場と動向分析:流通チャネル別
    • 病院薬局
    • 小売薬局
    • 通販薬局
  • 市場と予測:流通チャネル別
  • 市場の魅力分析
    • 国別
    • 製品タイプ別
    • 投与ルート別
    • 流通チャネル別
  • 推進要因と制約:影響分析

第13章 予測要因:関連性および影響

第14章 競争分析

  • 競争ダッシュボード
  • 企業の詳細研究
    • Amgen Inc.
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Sandoz International GmbH (Novartis AG)
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Teva Pharmaceutical Industries Ltd.
    • AMAG Pharmaceuticals
    • Rockwell Medical
    • Akebia Therapeutics
    • Vifor Pharma Management Ltd.

第15章 世界の腎性貧血治療市場の分析と予測:地域別

  • イントロダクション/主な調査結果
  • 過去の市場動向分析:地域別
  • 市場予測:地域別
    • 北米
    • 中南米
    • 欧州
    • 中国を除くアジア太平洋地域
    • 中国
    • 中東・アフリカ
  • 市場の魅力分析:地域別

第16章 市場分析と予測:製品タイプ別

  • イントロダクション/主な調査結果
  • 過去の市場:製品タイプ別
    • 鉄サプリメント
    • 赤血球刺激剤
  • 市場予測:製品タイプ別
  • 市場の魅力分析:製品タイプ別

第17章 市場分析と予測:投与ルート別

  • イントロダクション/主な調査結果
  • 過去の市場:投与ルート別
    • 経口
    • 非経口
  • 市場予測:投与ルート別
  • 市場の魅力分析:投与ルート別

第18章 市場分析と予測:流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場とトレンド分析:流通チャネル別
    • 病院薬局
    • 小売薬局
    • 通販薬局
  • 市場と予測:流通チャネル別
  • 市場の魅力分析:流通チャネル別

第19章 世界の腎性貧血治療市場の分析と予測

  • 市場価値シェア分析:全セグメント別
  • 前年比成長分析:全セグメント
  • 調査方法
図表

List of Table

  • Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021 (1/2)
  • Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021 (2/2)
  • Table 03: North America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 04: North America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Product Type
  • Table 05: North America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
  • Table 06: North America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 07: Latin America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 08: Latin America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Product Type
  • Table 09: Latin America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
  • Table 10: Latin America Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 11: Europe Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 12: Europe Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Product Type
  • Table 13: Europe Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
  • Table 14: Europe Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 15: APEC Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 16: APEC Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Product Type
  • Table 17: APEC Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
  • Table 18: APEC Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 19: China Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Product Type
  • Table 20: China Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
  • Table 21: China Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 22: MEA Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country
  • Table 23: MEA Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Product Type
  • Table 24: MEA Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
  • Table 25: MEA Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel
  • Table 26: Global Renal Anemia Treatment Market Size (US$ Mn) 2012-2016 and Forecast 2018-2026, By Region
  • Table 27: Global Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Product Type
  • Table 28: Global Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Route of Administration
  • Table 29: Global Renal Anemia Treatment Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

List of Figure

  • Figure 01: Global Renal Anemia Treatment Market Value Share By Product Type (2018 E)
  • Figure 02: Global Renal Anemia Treatment Market Value Share By Route of Administration (2018 E)
  • Figure 03: Global Renal Anemia Treatment Market Value Share By Distribution Channel (2018 E)
  • Figure 04: Global Renal Anemia Treatment Market Value Share By Region (2018 E)
  • Figure 05: Global Healthcare Expenditure in US$ Tn (2013-2020)
  • Figure 06: Distribution of Industry Sponsored Clinical Programs, by Phase
  • Figure 07: Number of Clinical Programs (phase II | phase III & phase III) expected to be completed by 2020, by company
  • Figure 08: Geographical Distribution of Clinical Trials for Renal Anemia Treatment (2017)
  • Figure 09: North America Renal Anemia Treatment Market Value Share By Product Type (2018 E)
  • Figure 10: North America Renal Anemia Treatment Market Value Share By Route of Administration (2018 E)
  • Figure 11: North America Renal Anemia Treatment Market Value Share By Distribution Channel (2018 E)
  • Figure 12: North America Renal Anemia Treatment Market Value Share By Country (2018 E)
  • Figure 13: North America Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 14: North America Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 15: U.S. Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 16: U.S. Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 17: Canada Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 18: Canada Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 19: North America Renal Anemia Treatment Market Attractiveness Analysis By Product Type, 2018-2026
  • Figure 20: North America Renal Anemia Treatment Market Attractiveness Analysis By Route of Administration, 2018-2026
  • Figure 21: North America Renal Anemia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 22: North America Renal Anemia Treatment Market Attractiveness Analysis By Country, 2018-2026
  • Figure 23: Latin America Renal Anemia Treatment Market Value Share By Product Type (2018 E)
  • Figure 24: Latin America Renal Anemia Treatment Market Value Share By Route of Administration (2018 E)
  • Figure 25: Latin America Renal Anemia Treatment Market Value Share By Distribution Channel (2018 E)
  • Figure 26: Latin America Renal Anemia Treatment Market Value Share By Country (2018 E)
  • Figure 27: Latin America Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 28: Latin America Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 29: Brazil Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 30: Brazil Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 31: Mexico Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 32: Mexico Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 33: Argentina Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 34: Argentina Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 35: Rest of Latin America Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 36: Rest of Latin America Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 37: Latin America Renal Anemia Treatment Market Attractiveness Analysis By Product Type, 2018-2026
  • Figure 38: Latin America Renal Anemia Treatment Market Attractiveness Analysis By Route of Administration, 2018-2026
  • Figure 39: Latin America Renal Anemia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 40: Latin America Renal Anemia Treatment Market Attractiveness Analysis By Country, 2018-2026
  • Figure 41: Europe Renal Anemia Treatment Market Value Share By Product Type (2018 E)
  • Figure 42: Europe Renal Anemia Treatment Market Value Share By Route of Administration (2018 E)
  • Figure 43: Europe Renal Anemia Treatment Market Value Share By Distribution Channel (2018 E)
  • Figure 44: Europe Renal Anemia Treatment Market Value Share By Country (2018 E)
  • Figure 45: Europe Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 46: Europe Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 47: U.K. Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 48: U.K. Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 49: Germany Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-201754
  • Figure 50: Germany Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 51: France Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 52: France Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 53: Italy Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 54: Italy Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 55: Spain Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 56: Spain Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 57: Russia Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 58: Russia Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 59: Poland Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 60: Poland Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 61: Rest of Europe Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 62: Rest of Europe Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 63: Europe Renal Anemia Treatment Market Attractiveness Analysis By Product Type, 2018-2026
  • Figure 64: Europe Renal Anemia Treatment Market Attractiveness Analysis By Route of Administration, 2018-2026
  • Figure 65: Europe Renal Anemia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 66: Europe Renal Anemia Treatment Market Attractiveness Analysis By Country, 2018-2026
  • Figure 67: APEC Renal Anemia Treatment Market Value Share By Product Type (2018 E)
  • Figure 68: APEC Renal Anemia Treatment Market Value Share By Route of Administration (2018 E)
  • Figure 69: APEC Renal Anemia Treatment Market Value Share By Distribution Channel (2018 E)
  • Figure 70: APEC Renal Anemia Treatment Market Value Share By Country (2018 E)
  • Figure 71: APEC Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 72: APEC Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 73: Japan Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 74: Japan Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 75: India Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 76: India Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 77: ANZ Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 78: ANZ Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 79: Rest of APEC Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 80: Rest of APEC Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 81: APEC Renal Anemia Treatment Market Attractiveness Analysis By Product Type, 2018-2026
  • Figure 82: APEC Renal Anemia Treatment Market Attractiveness Analysis By Route of Administration, 2018-2026
  • Figure 83: APEC Renal Anemia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 84: APEC Renal Anemia Treatment Market Attractiveness Analysis By Country, 2018-2026
  • Figure 85: China Renal Anemia Treatment Market Value Share By Product Type (2018 E)
  • Figure 86: China Renal Anemia Treatment Market Value Share By Route of Administration (2018 E)
  • Figure 87: China Renal Anemia Treatment Market Value Share By Distribution Channel (2018 E)
  • Figure 88: China Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 89: China Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 90: China Renal Anemia Treatment Market Attractiveness Analysis By Product Type, 2018-2026
  • Figure 91: China Renal Anemia Treatment Market Attractiveness Analysis By Route of Administration, 2018-2026
  • Figure 92: China Renal Anemia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 93: MEA Renal Anemia Treatment Market Value Share By Product Type (2018 E)
  • Figure 94: MEA Renal Anemia Treatment Market Value Share By Route of Administration (2018 E)
  • Figure 95: MEA Renal Anemia Treatment Market Value Share By Distribution Channel (2018 E)
  • Figure 96: MEA Renal Anemia Treatment Market Value Share By Country (2018 E)
  • Figure 97: MEA Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 98: MEA Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 99: South Africa Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 100: South Africa Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 101: GCC Countries Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 102: GCC Countries Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 103: Rest of MEA Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 104: Rest of MEA Renal Anemia Treatment Market Value Analysis (US$ Mn), 2018-2026
  • Figure 105: MEA Renal Anemia Treatment Market Attractiveness Analysis By Product Type, 2018-2026
  • Figure 106: MEA Renal Anemia Treatment Market Attractiveness Analysis By Route of Administration, 2018-2026
  • Figure 107: MEA Renal Anemia Treatment Market Attractiveness Analysis By Distribution Channel, 2018-2026
  • Figure 108: MEA Renal Anemia Treatment Market Attractiveness Analysis By Country, 2018-2026
  • Figure 109: Global Renal Anemia Treatment Market Share Analysis (%), By Region, 2018 & 2026
  • Figure 110: Global Renal Anemia Treatment Market Y-o-Y Analysis (%), By Region, 2018-2026
  • Figure 111: Global Renal Anemia Treatment Market Attractiveness Analysis By Region, 2018-2026
  • Figure 112: Global Renal Anemia Treatment Market Share Analysis (%), By Product Type, 2018 & 2026
  • Figure 113: Global Renal Anemia Treatment Market Y-o-Y Analysis (%), By Product Type, 2018-2026
  • Figure 114: Global Renal Anemia Treatment Market Attractiveness Analysis By Product Type, 2018-2026
  • Figure 115: Global Renal Anemia Treatment Market Share Analysis (%), By Route of Administration , 2018 & 2026
  • Figure 116: Global Renal Anemia Treatment Market Y-o-Y Analysis (%), By Route of Administration , 2018-2026
  • Figure 117: Global Renal Anemia Treatment Market Attractiveness Analysis By Route of Administration, 2018-2026
  • Figure 118: Global Renal Anemia Treatment Market Share Analysis (%), By Distribution Channel, 2018 & 2026
  • Figure 119: Global Renal Anemia Treatment Market Y-o-Y Analysis (%), By Distribution Channel, 2018-2026
  • Figure 120: Global Renal Anemia Treatment Market Attractiveness Analysis, By Distribution Channel, 2018-2026
  • Figure 121: Global Renal Anemia Treatment Market Value Analysis (US$ Mn), 2013-2017
  • Figure 122: Global Renal Anemia Treatment Market Value Analysis (US$ Mn), 2017-2026
  • Figure 123: Global Renal Anemia Treatment Market Absolute $ Opportunity, 2018 - 2026
目次

A recent market study published by PMR - "Renal Anemia Treatment Market: Global Industry Analysis 2013-2017 and Forecast 2018-2026" does a comprehensive assessment of the most important market dynamics. On conducting a thorough research on the historic as well as current growth parameters in the Renal Anemia Treatment market, growth prospects for the market have been obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the Renal Anemia Treatment market during the forecast period. The report will help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the Renal Anemia Treatment market in the upcoming years. The report provides detailed information about the current and future growth prospects for the Renal Anemia Treatment market in a most comprehensive way to facilitate better understanding of readers.

Chapter 01 - Executive Summary

The report commences with the executive summary of the Renal Anemia Treatment market, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the Renal Anemia Treatment market.

Chapter 02 - Market Introduction

Readers can find detailed taxonomy and the definition of the Renal Anemia Treatment market in this chapter. This chapter will help readers to understand the basic information about the Renal Anemia Treatment market. This chapter also highlights the inclusions and exclusions which will help the readers to understand the scope of the report.

Chapter 03 - Global Economic Outlook

This section highlights the expenditure on health for top countries in each region. This section also explains the global and regional healthcare market outlook. The chapter analyzes deeply the political, economic and business environment outlook for the various regions covered under the scope of the report.

Chapter 04 - Market Opportunity Analysis

This chapter explains the key macro-economic factors influencing the growth of the Renal Anemia Treatment market. Along with macroeconomic factors, this section also highlights the opportunity analysis for Renal Anemia Treatment market.

Chapter 05 - Market Dynamics

This chapter highlights the key market dynamics including the drivers, restraints and trends impacting the growth of Renal Anemia Treatment market. In this chapter, readers can find information about the various factors propelling the growth of the Renal Anemia Treatment market and the factors which may deter the growth of the market. This chapter will help readers understand market opportunities and thus, strategize accordingly.

Chapter 06 - Renal Anemia Treatment Market: Key Inclusions

This chapter highlights the key regulations for drug approval in the U.S. and Europe. This chapter also provides deep dive analysis on the products in pipeline in the Renal Anemia Treatment market. This chapter will help readers get an idea about the number of products in pipeline.

Chapter 07 - North America Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026

This chapter includes detailed analysis of the growth of the North America Renal Anemia Treatment market along with the country-wise assessment for the U.S. and Canada. Readers can also find information about regional trends, regulations and market growth based on product type, route of administration, end users and countries in the Renal Anemia Treatment market of North America.

Chapter 08 - Latin America Renal Anemia Treatment Market 2013-2017 & Forecast 2018-2026

Readers can find detailed information about regional trends impacting the growth of the Latin America Renal Anemia Treatment market. This chapter also discusses growth prospects for the Renal Anemia Treatment market in leading Latin American countries, such as Mexico, Argentina, Brazil and rest of Latin America.

Chapter 09 - Europe Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026

Important growth prospects for the Renal Anemia Treatment market, based on product type, application, technique, age group and end users in several countries, such as U.K., Germany, Spain, Italy, France, Russia, Poland and Rest of Europe, have been included in this chapter.

Chapter 10 - APEC Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026

Japan, India, Australia and Australia and rest of APEC are the leading countries in the APEC region and are the prime subject of assessment in this chapter on APEC Renal Anemia Treatment market. Readers can find thorough information about the growth parameters in the APEC Renal Anemia Treatment market during the period 2018-2026.

Chapter 11 - China Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026

This chapter provides information on how the Renal Anemia Treatment market will grow in the China Market during the period 2018-2026. This section will help readers get an understanding of the key factors responsible for the growth of Renal Anemia Treatment market in Europe.

Chapter 12 - MEA Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026

This chapter provides information on how the Renal Anemia Treatment market will grow in the major countries in MEA region, such as GCC Countries, South Africa and rest of MEA, during the period 2018-2026.

Chapter 13 - Forecast Factors - Relevance and Impact

This chapter highlights the key factors that were taken into consideration while forecasting market values for the global Renal Anemia Treatment market. The impact of the forecast factors in different regions has also been mentioned in this chapter. This section will help readers understand the assumptions taken into account while estimating and forecasting the market size of Renal Anemia Treatment market.

Chapter 14 - Competition Landscape

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the Renal Anemia Treatment market, along with detailed information about each company, including company overview, revenue shares, strategic overview, and recent company developments. Market players featured in thIS report include Amgen Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Sandoz International GmbH (Novartis AG), Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Teva Pharmaceutical Industries Ltd., AMAG Pharmaceuticals, Rockwell Medical, Akebia Therapeutics, Vifor Pharma Management Ltd. among others.

Chapter 15 - Global Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026, By Region

This chapter explains how the Renal Anemia Treatment market will grow across various geographic regions, such as North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa (MEA).

Chapter 16 - Global Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026, By Product Type

Based on product type, the Renal Anemia Treatment market is segmented into Iron Supplements and Erythrocyte Stimulating Agents. Further, the Erythrocyte Stimulating Agents segment is segmented into Epoetin Alfa, Epoetin Beta and Darbepoetin Alfa. In this chapter, readers can find information about key trends and developments in the Renal Anemia Treatment market and market attractive analysis based on product type for each region.

Chapter 17 - Global Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026, By Route of Administration

Based on the Route of Administration, the Renal Anemia Treatment market is segmented into Oral and Parenteral. In this chapter, readers can find information about key trends and developments in the Renal Anemia Treatment market and market attractive analysis based on the route of administration for each region.

Chapter 18 - Global Renal Anemia Treatment Market Analysis 2013-2017 & Forecast 2018-2026, By Distribution Channel

Based on the distribution channel, the Renal Anemia Treatment market is segmented into hospitals pharmacy, retail pharmacy and mail order pharmacy. In this chapter, readers can find information about key trends and developments in the Renal Anemia Treatment market and market attractive analysis based on end users for each region.

Chapter 19 - Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 20 - Research Methodology

This chapter will help readers get an understanding of the research methodology followed to obtain various conclusions, important qualitative information and quantitative information about the Renal Anemia Treatment market.

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Renal Anemia Treatment Market Opportunity Analysis

  • 3.1. Macro-Economic Factors
  • 3.2. Opportunity Analysis

4. Market Background

  • 4.1. Market Dynamics
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Trends

5. Key Inclusions

  • 5.1. Key Regulations
  • 5.2. Pipeline Analysis

6. Global Economic Outlook

  • 6.1. Gross Domestic Product by Region & Country, 2006 - 2021

7. North America Renal Anemia Treatment Market Analysis 2013-2017 and Forecast 2018-2026

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Mn) & Analysis By Country, 2013-2017
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Market Size (US$ Mn) & Forecast By Country, 2018-2026
  • 7.4. Historical Market Size (US$ Mn) By Product Type, 2013-2017
    • 7.4.1. Iron Supplements
    • 7.4.2. Erythrocyte Stimulating Agents
      • 7.4.2.1. Epoetin Alfa
      • 7.4.2.2. Epoetin Beta
      • 7.4.2.3. Darbepoetin Alfa
  • 7.5. Market Size (US$ Mn) Forecast By Product Type, 2018-2026
  • 7.6. Historical Market Size (US$ Mn) By Route of Administration, 2013-2017
    • 7.6.1. Oral
    • 7.6.2. Parenteral
  • 7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
  • 7.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
    • 7.8.1. Hospitals Pharmacy
    • 7.8.2. Retail Pharmacy
    • 7.8.3. Mail Order Pharmacy
  • 7.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018-2026
  • 7.10.Market Attractiveness Analysis
    • 7.10.1. By Country
    • 7.10.2. By Product Type
    • 7.10.3. By Route of Administration
    • 7.10.4. By Distribution Channel
  • 7.11.Drivers and Restraints: Impact Analysis

8. Latin America Renal Anemia Treatment Market Analysis 2013-2017and Forecast 2018-2026

  • 8.1. Introduction
  • 8.2. Historical Market Size (US$ Mn) Trends and Analysis By Country, 2013-2017
    • 8.2.1. Argentina
    • 8.2.2. Brazil
    • 8.2.3. Mexico
    • 8.2.4. Rest of Latin America
  • 8.3. Market Size (US$ Mn) & Forecast By Country, 2018-2026
  • 8.4. Historical Market Size (US$ Mn) By Product Type, 2013-2017
    • 8.4.1. Iron Supplements
    • 8.4.2. Erythrocyte Stimulating Agents
      • 8.4.2.1. Epoetin Alfa
      • 8.4.2.2. Epoetin Beta
      • 8.4.2.3. Darbepoetin Alfa
  • 8.5. Market Size (US$ Mn) Forecast By Product Type, 2018-2026
  • 8.6. Historical Market Size (US$ Mn) By Route of Administration, 2013-2017
    • 8.6.1. Oral
    • 8.6.2. Parenteral
  • 8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
  • 8.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
    • 8.8.1. Hospitals Pharmacy
    • 8.8.2. Retail Pharmacy
    • 8.8.3. Mail Order Pharmacy
  • 8.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018-2026
  • 8.10.Market Attractiveness Analysis
    • 8.10.1. By Country
    • 8.10.2. By Product Type
    • 8.10.3. By Route of Administration
    • 8.10.4. By Distribution Channel
  • 8.11.Drivers and Restraints: Impact Analysis

9. Europe Renal Anemia Treatment Market Analysis 2013-2017and Forecast 2018-2026

  • 9.1. Introduction
  • 9.2. Regional Trends
  • 9.3. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2013-2017
    • 9.3.1. Germany
    • 9.3.2. UK
    • 9.3.3. France
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Russia
    • 9.3.7. Poland
    • 9.3.8. Rest of Europe
  • 9.4. Market Size (US$ Mn) & Forecast By Country, 2018-2026
  • 9.5. Historical Market Size (US$ Mn) By Product Type, 2013-2017
    • 9.5.1. Iron Supplements
    • 9.5.2. Erythrocyte Stimulating Agents
      • 9.5.2.1. Epoetin Alfa
      • 9.5.2.2. Epoetin Beta
      • 9.5.2.3. Darbepoetin Alfa
  • 9.6. Market Size (US$ Mn) Forecast By Product Type, 2018-2026
  • 9.7. Historical Market Size (US$ Mn) By Route of Administration, 2013-2017
    • 9.7.1. Oral
    • 9.7.2. Parenteral
  • 9.8. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
  • 9.9. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
    • 9.9.1. Hospitals Pharmacy
    • 9.9.2. Retail Pharmacy
    • 9.9.3. Mail Order Pharmacy
  • 9.10. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018-2026
  • 9.11. Market Attractiveness Analysis
    • 9.11.1. By Country
    • 9.11.2. By Product Type
    • 9.11.3. By Route of Administration
    • 9.11.4. By Distribution Channel
  • 9.12. Drivers and Restraints: Impact Analysis

10. Asia Pacific Excluding China Renal Anemia Treatment Market Analysis 2013-2017 and Forecast 2018-2026

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Trend Analysis By Country, 2013-2017
    • 10.2.1. India
    • 10.2.2. Japan
    • 10.2.3. Australia and New Zealand
    • 10.2.4. Rest of APAC
  • 10.3. Market Size (US$ Mn) & Forecast By Country, 2018-2026
  • 10.4. Historical Market Size (US$ Mn) By Product Type, 2013-2017
    • 10.4.1. Iron Supplements
    • 10.4.2. Erythrocyte Stimulating Agents
      • 10.4.2.1. Epoetin Alfa
      • 10.4.2.2. Epoetin Beta
      • 10.4.2.3. Darbepoetin Alfa
  • 10.5. Market Size (US$ Mn) Forecast By Product Type, 2018-2026
  • 10.6. Historical Market Size (US$ Mn) By Route of Administration, 2013-2017
    • 10.6.1. Oral
    • 10.6.2. Parenteral
  • 10.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
  • 10.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
    • 10.8.1. Hospitals Pharmacy
    • 10.8.2. Retail Pharmacy
    • 10.8.3. Mail Order Pharmacy
  • 10.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018-2026
  • 10.10. Market Attractiveness Analysis
    • 10.10.1. By Country
    • 10.10.2. By Product Type
    • 10.10.3. By Route of Administration
    • 10.10.4. By Distribution Channel
  • 10.11. Drivers and Restraints: Impact Analysis

11. China Renal Anemia Treatment Market Analysis 2013-2017 and Forecast 2018-2026

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) By Product Type, 2013-2017
    • 11.2.1. Iron Supplements
    • 11.2.2. Erythrocyte Stimulating Agents
      • 11.2.2.1. Epoetin Alfa
      • 11.2.2.2. Epoetin Beta
      • 11.2.2.3. Darbepoetin Alfa
  • 11.3. Market Size (US$ Mn) Forecast By Product Type, 2018-2026
  • 11.4. Historical Market Size (US$ Mn) By Route of Administration, 2013-2017
    • 11.4.1. Oral
    • 11.4.2. Parenteral
  • 11.5. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
  • 11.6. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
    • 11.6.1. Hospitals Pharmacy
    • 11.6.2. Retail Pharmacy
    • 11.6.3. Mail Order Pharmacy
  • 11.7. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018-2026
  • 11.8. Market Attractiveness Analysis
    • 11.8.1. By Product Type
    • 11.8.2. By Route of Administration
    • 11.8.3. By Distribution Channel
  • 11.9. Drivers and Restraints: Impact Analysis

12. Middle East & Africa Renal Anemia Treatment Market Analysis 2013-2017 and Forecast 2018-2026

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) and Trend Analysis By Country, 2013-2017
    • 12.2.1. GCC Countries
    • 12.2.2. South Africa
    • 12.2.3. Rest of MEA
  • 12.3. Market Size (US$ Mn) & Forecast By Country, 2018-2026
  • 12.4. Historical Market Size (US$ Mn) By Product Type, 2013-2017
    • 12.4.1. Iron Supplements
    • 12.4.2. Erythrocyte Stimulating Agents
      • 12.4.2.1. Epoetin Alfa
      • 12.4.2.2. Epoetin Beta
      • 12.4.2.3. Darbepoetin Alfa
  • 12.5. Market Size (US$ Mn) Forecast By Product Type, 2018-2026
  • 12.6. Historical Market Size (US$ Mn) By Route of Administration, 2013-2017
    • 12.6.1. Oral
    • 12.6.2. Parenteral
  • 12.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
  • 12.8. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
    • 12.8.1. Hospitals Pharmacy
    • 12.8.2. Retail Pharmacy
    • 12.8.3. Mail Order Pharmacy
  • 12.9. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018-2026
  • 12.10. Market Attractiveness Analysis
    • 12.10.1. By Country
    • 12.10.2. By Product Type
    • 12.10.3. By Route of Administration
    • 12.10.4. By Distribution Channel
  • 12.11. Drivers and Restraints: Impact Analysis

13. Forecast Factors: Relevance and Impact

14. Competition Analysis

  • 14.1. Competition Dashboard
  • 14.2. Company Deep Dive
    • 14.2.1. Amgen Inc.
      • 14.2.1.1. Overview
      • 14.2.1.2. Product and Application Portfolio
      • 14.2.1.3. Production Footprint
      • 14.2.1.4. Sales Footprint
      • 14.2.1.5. Channel Footprint
      • 14.2.1.6. Strategy
        • 14.2.1.6.1. Marketing Strategy
        • 14.2.1.6.2. Product Strategy
        • 14.2.1.6.3. Channel Strategy
    • 14.2.2. F. Hoffmann-La Roche Ltd
      • 14.2.2.1. Overview
      • 14.2.2.2. Product and Application Portfolio
      • 14.2.2.3. Production Footprint
      • 14.2.2.4. Sales Footprint
      • 14.2.2.5. Channel Footprint
      • 14.2.2.6. Strategy
        • 14.2.2.6.1. Marketing Strategy
        • 14.2.2.6.2. Product Strategy
        • 14.2.2.6.3. Channel Strategy
    • 14.2.3. Pfizer Inc.
      • 14.2.3.1. Overview
      • 14.2.3.2. Product and Application Portfolio
      • 14.2.3.3. Production Footprint
      • 14.2.3.4. Sales Footprint
      • 14.2.3.5. Channel Footprint
      • 14.2.3.6. Strategy
        • 14.2.3.6.1. Marketing Strategy
        • 14.2.3.6.2. Product Strategy
        • 14.2.3.6.3. Channel Strategy
    • 14.2.4. Sandoz International GmbH (Novartis AG)
      • 14.2.4.1. Overview
      • 14.2.4.2. Product and Application Portfolio
      • 14.2.4.3. Production Footprint
      • 14.2.4.4. Sales Footprint
      • 14.2.4.5. Channel Footprint
      • 14.2.4.6. Strategy
        • 14.2.4.6.1. Marketing Strategy
        • 14.2.4.6.2. Product Strategy
        • 14.2.4.6.3. Channel Strategy
    • 14.2.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
      • 14.2.5.1. Overview
      • 14.2.5.2. Product and Application Portfolio
      • 14.2.5.3. Production Footprint
      • 14.2.5.4. Sales Footprint
      • 14.2.5.5. Channel Footprint
      • 14.2.5.6. Strategy
        • 14.2.5.6.1. Marketing Strategy
        • 14.2.5.6.2. Product Strategy
        • 14.2.5.6.3. Channel Strategy
    • 14.2.6. Teva Pharmaceutical Industries Ltd.
      • 14.2.6.1. Overview
      • 14.2.6.2. Product and Application Portfolio
      • 14.2.6.3. Production Footprint
      • 14.2.6.4. Sales Footprint
      • 14.2.6.5. Channel Footprint
      • 14.2.6.6. Strategy
        • 14.2.6.6.1. Marketing Strategy
        • 14.2.6.6.2. Product Strategy
        • 14.2.6.6.3. Channel Strategy
    • 14.2.7. AMAG Pharmaceuticals
      • 14.2.7.1. Overview
      • 14.2.7.2. Product and Application Portfolio
      • 14.2.7.3. Production Footprint
      • 14.2.7.4. Sales Footprint
      • 14.2.7.5. Channel Footprint
      • 14.2.7.6. Strategy
        • 14.2.7.6.1. Marketing Strategy
        • 14.2.7.6.2. Product Strategy
        • 14.2.7.6.3. Channel Strategy
    • 14.2.8. Rockwell Medical
      • 14.2.8.1. Overview
      • 14.2.8.2. Product and Application Portfolio
      • 14.2.8.3. Production Footprint
      • 14.2.8.4. Sales Footprint
      • 14.2.8.5. Channel Footprint
      • 14.2.8.6. Strategy
        • 14.2.8.6.1. Marketing Strategy
        • 14.2.8.6.2. Product Strategy
        • 14.2.8.6.3. Channel Strategy
    • 14.2.9. Akebia Therapeutics
      • 14.2.9.1. Overview
      • 14.2.9.2. Product and Application Portfolio
      • 14.2.9.3. Production Footprint
      • 14.2.9.4. Sales Footprint
      • 14.2.9.5. Channel Footprint
      • 14.2.9.6. Strategy
        • 14.2.9.6.1. Marketing Strategy
        • 14.2.9.6.2. Product Strategy
        • 14.2.9.6.3. Channel Strategy
    • 14.2.10. Vifor Pharma Management Ltd.
      • 14.2.10.1. Overview
      • 14.2.10.2. Product and Application Portfolio
      • 14.2.10.3. Production Footprint
      • 14.2.10.4. Sales Footprint
      • 14.2.10.5. Channel Footprint
      • 14.2.10.6. Strategy
        • 14.2.10.6.1. Marketing Strategy
        • 14.2.10.6.2. Product Strategy
        • 14.2.10.6.3. Channel Strategy

15. Global Renal Anemia Treatment Market Analysis 2013-2017and Forecast 2018-2026, By Region

  • 15.1. Introduction/Key Findings
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013-2017
  • 15.3. Market Size (US$ Mn) Forecast By Region, 2018-2026
    • 15.3.1. North America
    • 15.3.2. Latin America
    • 15.3.3. Europe
    • 15.3.4. Asia Pacific Excluding China
    • 15.3.5. China
    • 15.3.6. Middle East & Africa
  • 15.4. Market Attractiveness Analysis By Region

16. Global Renal Anemia Treatment Market Analysis 2013-2017and Forecast 2018-2026, By Product Type

  • 16.1. Introduction/Key Findings
  • 16.2. Historical Market Size (US$ Mn) By Product Type, 2013-2017
    • 16.2.1. Iron Supplements
    • 16.2.2. Erythrocyte Stimulating Agents
      • 16.2.2.1. Epoetin Alfa
      • 16.2.2.2. Epoetin Beta
      • 16.2.2.3. Darbepoetin Alfa
  • 16.3. Market Size (US$ Mn) Forecast By Product Type, 2018-2026
  • 16.4. Market Attractiveness Analysis By Product Type

17. Global Renal Anemia Treatment Market Analysis 2013-2017and Forecast 2018-2026, By Route of Administration

  • 17.1. Introduction/Key Findings
  • 17.2. Historical Market Size (US$ Mn) By Route of Administration, 2013-2017
    • 17.2.1. Oral
    • 17.2.2. Parenteral
  • 17.3. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2026
  • 17.4. Market Attractiveness Analysis By Route of Administration

18. Global Renal Anemia Treatment Market Analysis 2013-2017and Forecast 2018-2026, By Distribution Channel

  • 18.1.Introduction/Key Findings
  • 18.2. Historical Market Size (US$ Mn) and Trend Analysis By Distribution Channel, 2013-2017
    • 18.2.1. Hospitals Pharmacy
    • 18.2.2. Retail Pharmacy
    • 18.2.3. Mail Order Pharmacy
  • 18.3. Market Size (US$ Mn) and Forecast By Distribution Channel, 2018-2026
  • 18.4. Market Attractiveness Analysis By Distribution Channel

19. Global Renal Anemia Treatment Market Analysis 2013-2017and Forecast 2018-2026

  • 19.1.Market Value Share Analysis By All Segment
  • 19.2. Y-o-Y Growth Analysis By All Segment
  • 19.3. Absolute $ Opportunity
  • 19.4. Research Methodology
Back to Top